Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544567 · ClinicalTrials.gov registry record · Phase 2
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 study of Angiosarcoma of Skin, sponsored by Athenex.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 10
- Study locations
NCT03544567 is a Phase 2 study of Angiosarcoma of Skin that has completed, run by Athenex. The registered enrollment target is 48 participants. The trial reports 10 study locations across 4 states.
The verdict
NCT03544567, a Phase 2 study of Angiosarcoma of Skin, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
Conditions Studied
Interventions
- DRUG Oraxol
Study Locations (10)
Other
- Prince of Wales Hospital, Shatin - Hong Kong
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hosptial - Taipei
- University College London Hospitals NHS Foundation Trust - London
- The Royal Marsden NHS Foundation Trust - London
- The Christie NHS Foundation Trust, Manchester - Manchester
Texas
- Texas Oncology - Dallas
- MD Anderson Cancer Center - Houston
New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- University of Washington/Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03544567
The ClinicalTrials.gov registry entry for NCT03544567 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Athenex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angiosarcoma of Skin appearing as the primary indexed condition, and to 1 intervention - of which Oraxol is the first listed.
NCT03544567 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT03544567 about?
NCT03544567 is a clinical study titled "A Study of Oraxol in Subjects With Cutaneous Angiosarcoma". This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
What is the current status of trial NCT03544567?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2018-12-21. Estimated completion is 2023-05-12.
What conditions does trial NCT03544567 study?
This clinical trial studies the following conditions: Angiosarcoma of Skin.
What interventions are being tested in trial NCT03544567?
The interventions under investigation include: Oraxol (DRUG).
Who is sponsoring clinical trial NCT03544567?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03544567 being conducted?
This trial has 10 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.